WELCOME TO D42C
The Forty To See, Inc.
The Forty To See, Inc. (aka D42C) provides Pharmaceutical Consulting to a variety of international clients. We are and have been strategic partners for mergers & acquisitions; product licensing; pipeline development; offshore cross-Atlantic expansion initiatives; and start-up and exit scenarios. D42C possesses the necessary faculties to support its clients in those endeavors. Our relationships and industry knowledge represent more than a combined six decades of involvement in the pharmaceutical industry in North America and Europe.
/1/
Continue with next section: Our Services
Our Services
Transatlantic services directed towards markets in North America and Europe
In a day and age in which cross-cultural competence is essential to successfully execute corporate transactions, D42C can assist since its principals have lived and worked in various geographies; and speak several languages. Such competence has helped to produce a number of impressive success stories for its clients originating from the German, Anglo-Saxon and Latin cultures. D42C has served the pharmaceutical, biotech, research tools and regenerative medicine spaces within the industry.
🔖 en/services
Corporate Transactions
Both, buy and sell side
Typically, in conjunction with M&A mandates
Typically, in conjunction with Turnaround and/or M&A mandates
Business Development
Business Establishment
Typically and historically, business set-up from Europe into North America with focus on the U.S. market
International Expansion
From Europe into markets in North and South America; from North American markets into South America; and from North American markets into Europe.
Intelligence
IP
In-house capability for full patent review; patent evaluation; and comprehensive IP recommendation
U.S. PTO as well as EPO
Due Dilligence
Typically, in conjunction with corporate transactions or business development projects; however, also as a standalone service
Continue with next section: Our Clients
Our Clients
D42C can typically address consulting needs of clients in the small (including start-up) and medium (established) size segment of the industry; and small to medium sized private, venture capital and private equity investors. Even though discretion in our dealings is a guiding business principle whereby D42C does not disclose the identity of clients, nature of assignments or specifics of projects, the following will provide a general description of the typical and historical assignments performed. Upon the establishment of a bona fide interest with a potential client in the services of D42C, further information on the general nature of specific assignments may be provided.
🔖 en/clients
EXECUTION
Execution
Acquisition of a major multinational injectable manufacturer
Established U.S. business for a European based CDMO
Established U.S. agency for API and Finished Dose products
Sale of established European based multinational research tools company
Exit for investors of a U.S. start-up research tools company
Exit, turnaround and interim management for a European based biotech company
ADVICE
Advice
European based custom API manufacturer for establishing business in the U.S. market
Asian based API manufacturer for approach to potential customers in the U.S. market
Private / VC / PE investors on various U.S. and European investment opportunities
Indian based company on entry into the U.S. hospital market
Various opportunities in regenerative medicine and stem cell business; U.S. and Europe
STRATEGIC ANALYSIS
Strategic Analysis (IP; competition; regulatory; timing)
Bio-similar biologic products
Bio-better biologic products
Very difficult to manufacture oral and injectable generic products
Devices
Continue with next section: Team
Denise Scheiner, President
Learn moreWith three decades of healthcare industry experience, Denise addresses all technical and scientific aspects of D42C’s consulting assignments. Her professional background includes management positions in the laboratory diagnostics and pharmaceutical products spaces of the industry. Her experience spans from QC/QA; regulatory affairs; product development; project management to IP. She worked for corporations such as SmithKline; Gebauer; and Boehringer Ingelheim (both, Bedford Laboratories and Roxane Laboratories).
Christian Scheiner, Chairman
Learn moreWith over three decades of pharmaceutical industry experience, Christian addresses all business and deal related aspects of D42C’s consulting assignments. His professional background includes executive management positions in research based and generic pharmaceuticals, biotechnology and regenerative medicine. He has management experience in both start-up and established businesses. For Boehringer Ingelheim and STADA AG, he has been assigned to European, North and Latin American markets in executive operating and strategic roles.
Jobs
Sorry, no open positions at this time.
Continue with next section: Why D42C
Why D42C
D42C offers personalized consulting to its clients. The business structure of our assignments creates a no pressure environment for clients. We will see an assignment through even if the going gets tough.
We are focused on results and pride ourselves with delivering. When we believe of being able to successfully perform an assignment, we usually do.
🔖 en/why
Deep knowledge of the pharmaceutical industry
Multi-functional operating and strategic expertise
Extensive transatlantic experience
Diverse cultural competence
Broad involvement in all segments of the industry.
Impressive deal record
D42C The Forty To See, Inc. | Copyright © 2004-2024, D42C and/or its affiliates. All rights reserved. Powered by SNEWMEDIA.